Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals, Pulsus Group Inc
       
  Pulsus Group Inc. The Medical Peer Review Publisher
                                                                                                                       
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
  Search The Canadian Journal of Infectious Diseases & Medical Microbiology
Search    
Advanced Search PROFESSIONAL SITE
CONSUMER SITE
 
 
 
 
THE CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY
Association of Medical Microbiology & Infectious Diseases (AMMI Canada)
                                                                                   
                                                                                   
                                                                                   
 
   Home   
   Current Issue   
   Past Issues   
   Guidelines   
   Supplements   
   Submit Manuscript   
   Calendar   
   Links   
 
 
 
Return to TOC
   PDF / Free   
 
Special Article September/October 2007, Volume 18 Issue 5: 293-303
 
Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals
P Côté, J Baril, M Hébert, M Klein, R Lalonde, M Poliquin, D Rouleau, R Therrien, S Vézina, B Willems, H Dion, P Junod, N Lapointe, D Lévesque, L Pinault, C Tremblay, B Trottier, S Trottier, C Tsoukas, A Piché

Concomitant HIV and hepatitis C virus (HCV) is a common yet complex coinfection. The present document is a practical guide for treating HCV infection in people coinfected with HIV. Effective antiretroviral therapies have prolonged survival rates for HIV-infected people over the past decade, which have made latent complications of HCV major causes of morbidity and mortality in these patients. Advances in the treatment of HCV (eg, combined pegylated interferon and ribavirin) offer the possibility of eradicating HCV infection in coinfected persons. The treatment of HCV must be considered in all cases. Intensive management of the adverse effects of HCV treatment is one of the factors for the success of these therapies. HCV eradication is predicted to decrease the mortality associated with coinfection and reduce the toxicity of HIV treatment.

   Français        E-Mail This Abstract To A Colleague
            Click here to download free Adobe PDF Reader
 
 
 
 
  Log in
  Register
  Sign up for eTOC
  Survey
  Shopping Cart
Copyright © Pulsus Group Inc